Merck To Present New Clinical, Real-World Data Reaffirming Long-Term Effectiveness Of 9-Valent HPV Vaccine, GARDASIL9 And 4-Valent HPV Vaccine, GARDASIL At EUROGIN International Multidisciplinary HPV Congress 2026

Merck (NYSE: MRK) will present new clinical and real-world data on the long-term effectiveness of its 9-valent HPV vaccine, GARDASIL9, and 4-valent HPV vaccine, GARDASIL, at the EUROGIN International Multidisciplinary HPV Congress 2026 in Vienna from March 18-21. The data indicates that the 9-valent vaccine remains effective for at least 14 years, while the 4-valent vaccine shows effectiveness up to 18 years after three doses. Additionally, the presentation will include findings related to HPV-related oropharyngeal cancers and Recurrent Respiratory Papillomatosis (RRP) from studies conducted in multiple countries.